Patents Issued in October 9, 2018
  • Compounds useful as inhibitors of ATR kinase
    Patent number: 10093676
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-1 or I-A: wherein the variables are as defined herein.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: October 9, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Nadia Ahmad, Jean-Damien Charrier, Chris Davis, Gorka Etxebarria I Jardi, Damien Fraysse, Ronald Knegtel, Maninder Panesar, Francoise Pierard, Joanne Pinder, Pierre-Henri Storck, John Studley
  • Method for preparing spiro quaternary ammonium salt
    Patent number: 10093677
    Abstract: The present invention relates to a method for preparing a spiro quaternary ammonium salt comprising reacting a cyclic secondary amine with a dihaloalkane in the presence of a basic resin. According to the preparation method of the present invention, a metal salt and halide ion are removed by filtration without any additional purification process, the spiro ammonium derivative compound can be obtained with high yield, and the resin can be reused through a simple treatment process.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: October 9, 2018
    Assignee: SAMHWA PAINTS INDUSTRIES CO., LTD.
    Inventors: Myeng Chan Hong, Young Seop Choi, Seung Hun Lee, Da Eun Kwon, So Hyun Jang, June Hyeop An, Chong Yun Kwag
  • Azaspiro derivatives as TRPM8 antagonists
    Patent number: 10093678
    Abstract: The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: October 9, 2018
    Assignee: RaQualia Pharma Inc.
    Inventors: Yuji Shishido, Masashi Ohmi, Kazuo Ando
  • Amino sulfonyl-based compounds, the preparation method therefor and use thereof
    Patent number: 10093679
    Abstract: Disclosed are aminosulfonyl-based compounds represented by the general formula I or tautomers, enantiomers, racemates or pharmaceutically acceptable salts thereof, a method for preparing the same, pharmaceutical compositions and uses thereof. The compounds can be used to treat epilepsy, convulsions, obesity and the like.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 9, 2018
    Assignees: SUZHOU VIGONVITA LIFE SCIENCES CO., LTD, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, TOPHARMAN SHANGHAI CO., LTD
    Inventors: Jingshan Shen, Zheng Liu, Zhen Wang, Guanghui Tian, Jianfeng Li, Xiaojun Yang
  • Asymmetric benzotrichalcogenophene compound, synthesis method thereof and polymer
    Patent number: 10093680
    Abstract: A synthesis method of benzotrichalcogenophene (BTC) includes using a tetrakis(triphenylphosphine)palladium (Pd(PPh3)4) catalyst and a [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloro[3-phenylallyl]palladium(II) (Pd-IPr) catalyst. The asymmetric benzotrichalcogenophene compound is a heterocyclic compound having furan, thiophene, selenophene and/or tellurophene subunits.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: October 9, 2018
    Assignee: NATIONAL CHIAO TUNG UNIVERSITY
    Inventors: Yen-Ju Cheng, Yu-Chieh Pao, Shi-Yen Chen
  • Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
    Patent number: 10093681
    Abstract: The present invention provides oxazine compounds, method of using and method of making oxazine compounds and its pharmaceutical use.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: October 9, 2018
    Assignee: Southern Methodist University
    Inventors: Edward R. Biehl, Haribabu Ankati, Sukanta Kamila
  • Method for synthesizing tetrahydroisoquinoline oxazolidine
    Patent number: 10093682
    Abstract: The invention relates to a method for synthesizing tetrahydroisoquinoline oxazolidine. The method is carried out at a room temperature between 20° C. and 35° C.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: October 9, 2018
    Assignee: NATIONAL CHI NAN UNIVERSITY
    Inventors: Te-Fang Yang, Sheng-Han Huang, Yan-Liang Lin, Wen-Tse Huang, Yu-Wei Shih
  • Factor XIa inhibitors
    Patent number: 10093683
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: October 9, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yeon-Hee Lim, Zhuyan Guo, Amjad Ali, Scott D. Edmondson, Weiguo Liu, Gioconda V. Gallo-Etienne, Heping Wu, Ying-Duo Gao, Andrew W. Stamford, Younong Yu, Nancy J. Kevin, Rajan Anand, Deyou Sha, Santhosh F. Neelamkavil, Zahid Hussain, Puneet Kumar, Remond Moningka, Joseph L. Duffy, Jiayi Xu, Yu Jiang, Anjan Chakrabarti, Hiroki Sone
  • Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
    Patent number: 10093684
    Abstract: Certain imidazopyrazines of Formula I and pharmaceutical compositions thereof are provided herein: Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: October 9, 2018
    Assignee: Gilead Connecticut, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Douglas G. Stafford, Jianjun Xu
  • Beta-lactamase inhibitors
    Patent number: 10093685
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 9, 2018
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Heteroaryl inhibitors of PDE4
    Patent number: 10093686
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: October 9, 2018
    Assignee: Tetra Discovery Partners, LLC
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert F. Campbell, Joel R. Walker, Lei Zhu
  • Metal N-aminoguanidinate complexes for use in thin film fabrication and catalysis
    Patent number: 10093687
    Abstract: The present patent application relates to new metal complexes having at least one N-aminoguanidinate ligand. The patent application further relates to the preparation of the new metal complexes and also to their use. The new metal complexes are especially suitable as precursors for the preparation of functional layers by means of gas-phase thin-film processes such as CVD, MO-CVD, MOVPE and ALD. Additionally, they are also suitable as catalysts for olefin hydroamination and for olefin polymerization.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: October 9, 2018
    Assignee: UMICORE AG & CO. KG
    Inventors: Joerg Sundermeyer, Katrin Schlechter
  • Non-aqueous liquid electrolyte, electricity storage device using same, and phosphorus compound used therein
    Patent number: 10093688
    Abstract: A nonaqueous electrolytic solution having an electrolyte salt dissolved in a nonaqueous solvent, containing a compound of formula (X): where R10 and R20 are each a group selected from an alkyl having 1 to 8 carbon atoms, an alkenyl having 2 to 6 carbon atoms, an alkynyl having 3 to 6 carbon atoms, and an aryl having 6 to 12 carbon atoms, or a lithium; and X is a polar group (i) containing a —C(?O), a —P(?O), or an —S(?O)2 group, a polar group (ii) containing a —CN or an alkyl group having 1 to 6 carbon atoms, in which a part of hydrogen atoms is substituted with a fluorine atom, or a 4- to 7-membered ring polar group (iii) containing a —C(?O)—O— or a —C(?O)—N— group, where when X is a 4- to 7-membered ring polar group (iii) containing —C(?O)—N—, at least one of R10 and R20 is lithium.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: October 9, 2018
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Yuichi Kotou, Tatsuo Fujino, Kei Shimamoto, Shuichi Koso, Shoji Shikita, Yosuke Sato, Junichi Chika
  • Composition containing a gold (I) complex and cancer cells
    Patent number: 10093689
    Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: October 9, 2018
    Assignees: King Fahd University of Petroleum and Minerals, King Saud University
    Inventors: Said S. Al-Jaroudi, Ali Alhoshani, Muhammad Altaf, Anvarhusein Abdulkadir Isab
  • Heterocyclic selenaphosphites and process for preparation thereof
    Patent number: 10093690
    Abstract: Novel heterocyclic selenaphosphites, process for preparation thereof and use thereof as ligand for employment in complexes.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: October 9, 2018
    Assignee: EVONIK DEGUSSA GMBH
    Inventors: Katrin Marie Dyballa, Robert Franke, Claudia Weilbeer, Detlef Selent, Armin Börner
  • Crystallization method and bioavailability
    Patent number: 10093691
    Abstract: Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 9, 2018
    Assignee: GRUNENTHAL GMBH
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna, Raymond Houck
  • Phosphines, synthesis thereof and their use in catalysis
    Patent number: 10093692
    Abstract: The present invention relates to a novel class of benzimidazolyl/imidazolyl phosphine ligands, methods of preparing such ligands via a simple one-pot protocol, and applications of the ligands in catalytic reactions.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: October 9, 2018
    Assignee: The Hong Kong Polytechnic University
    Inventors: Fuk Yee Kwong, Shun Man Wong, Chung Chiu Yeung
  • Electrochromic compound, electrochromic composition, and display element
    Patent number: 10093693
    Abstract: To provide an electrochromic compound, represented by the following general formula (I): General Formula (I) where X1, X2, X3, X4, X5, X6, X7 and X8 are each independently a hydrogen atom or a monovalent substituent; R1 and R2 are each independently a monovalent substituent; A? and B? are each independently a monovalent anion; and Y is represented by the following general formula (II) or (III): General Formula (II) General Formula (III) where X9, X10, X11, X12, X13, X14, X15, X16, X17, and X18 are each independently a hydrogen atom or a monovalent substituent.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: October 9, 2018
    Assignee: Ricoh Company, Ltd.
    Inventors: Toshiya Sagisaka, Hiroyuki Takahashi, Takashi Okada, Shigenobu Hirano, Tohru Yashiro, Koh Fujimura, Yoshihisa Naijo, Yoshinori Okada, Kazuaki Tsuji, Sukchan Kim, Keiichiroh Yutani, Tamotsu Horiuchi, Mamiko Inoue
  • Compounds for treating eye disorders or diseases
    Patent number: 10093694
    Abstract: Described herein are compounds that inhibit or prevent protein aggregation, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with protein aggregation.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 9, 2018
    Assignees: GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO, LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Rui Hou, Kang Zhang, Gen Li
  • Sterol derivative, preparation method therefor and use thereof
    Patent number: 10093695
    Abstract: The present disclosure discloses a sterol derivative, a preparation method therefor and a use thereof. The sterol derivative includes a sterol compound with Structural Formula (I) or a pharmaceutically acceptable salt thereof, or an extract containing the sterol compound, or a composition containing the sterol compound, wherein Structural Formula (I) is as follows: where R1 is —OH, ?O, H or C1-C3 alkyl; R2 is —OH, H or C1-C3 alkyl; R3 is —OH, ?O, H or C1-C3 alkyl; R4 is —OH, H or C1-C3 alkyl, and at least one of R1, R2, R3 and R4 is —OH. The compound with Structural Formula (I) can be used for preparing a drug having inhibitory effect on 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity and the prepared drug can effectively inhibit the HMG-CoA reductase activity or be used for preparing an anti-cancer drug.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: October 9, 2018
    Assignee: BEIJING PEKING UNIVERSITY WBL BIOTECH CO., LTD.
    Inventors: Zhenwen Duan, Shuren Guo, Xuemei Li
  • Nitric oxide donating carnosine compounds
    Patent number: 10093696
    Abstract: The present invention relates to nitric oxide donor carnosine derivatives having a great efficacy in reducing elevated intraocular pressure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: October 9, 2018
    Assignee: NICOX SCIENCE IRELAND
    Inventors: Nicoletta Almirante, Laura Storoni, Elena Bastia, Stefania Brambilla, Sergio Romeo
  • IBAT inhibitors for the treatment of liver diseases
    Patent number: 10093697
    Abstract: The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 9, 2018
    Inventors: Per-Göran Gillberg, Hans Graffner, Ingemar Starke
  • Peptide having efficacy for remedying hypopigmentation and inhibiting adipogenesis, and use of same
    Patent number: 10093698
    Abstract: A peptide formed from the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 shows a melanogenesis increment activity and an adipogenesis inhibitory activity. The peptide, by increasing phosphorylation of MITF, which is a transcription factor for increasing a tyrosinase expression, and CREB for increasing an MITF expression, consequently increases a tyrosinase expression and ultimately increases melanin synthesis. The peptide, by reducing the amount of fat accumulated inside a cell and reducing expressions of perilipin and PPAR?, which contribute to adipogenic mechanism, ultimately inhibits adipogenesis. A composition for remedying or treating melanin hypopigmentation, a composition comprising the peptide, and a pharmaceutical composition for treating or preventing obesity, are provided.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 9, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee, Kyoung Mi Cho
  • Peptides with antimicrobial, anticancer and/or wound-healing promoting activities, pharmaceutical compositions containing the same, and use of the peptides with antimicrobial, anticancer and/or wound-healing promoting activities
    Patent number: 10093699
    Abstract: A peptide with antimicrobial, anticancer and/or wound-healing promoting activities is provided. The peptide with antimicrobial, anticancer and/or wound-healing promoting activities, includes: an ?-helix peptide; and a short peptide consisting of about 4-10 positively charged amino acids, connected to an N-terminus of the ?-helix peptide to form the peptide with antimicrobial, anticancer and/or wound-healing promoting activities, wherein the total length of the peptide with antimicrobial, anticancer and/or wound-healing promoting activities is about 10-20 amino acids.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: October 9, 2018
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Jya-Wei Cheng, Hui-Yuan Yu, Hung-Lun Chu
  • Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids
    Patent number: 10093700
    Abstract: The present invention relates to ?-PNA monomers according to Formula I where substituent groups R1, R2, R3, R4, R5, R6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: October 9, 2018
    Assignee: CARNEGIE MELLON UNIVERSITY
    Inventors: Danith H. Ly, Srinivas Rapireddy, Bichismita Sahu
  • Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
    Patent number: 10093701
    Abstract: Disclosed herein are compositions, cells, kits, and methods for inducing an immune response in a subject. The compositions can be used as vaccines or vaccine adjuvants against cancer (e.g., melanoma, glioma, prostate, breast) and infectious diseases (e.g., therapeutic and preventative vaccination for viruses), and can be used in cell-based therapies for preventing and treating disorders such as cancer and infection. The compositions, cells, kits and methods involve one or more nucleic acids that encode one or more LMP1 fusion proteins (chimeric proteins), and in a typical embodiment, synergistic activation of immune responses by a combination of two or more LMP1 fusion proteins.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: October 9, 2018
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Geoffrey W. Stone, Sachin Gupta
  • immunogens and related materials and methods
    Patent number: 10093702
    Abstract: The present invention provides compositions useful to induce immune response to human metapneumovirus. Also provided are related materials and methods, including methods to induce an immune response in a mammal, comprising administering the compositions herein.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 9, 2018
    Assignees: Research Institute at Nationwide Children's Hospital, Ohio State Innovation Foundation
    Inventors: Jianrong Li, Yongwei Wei, Yu Zhang, Mark E. Peeples
  • Computationally optimized broadly reactive antigens for H1N1 influenza
    Patent number: 10093703
    Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: October 9, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar
  • Expression and purification of CRM197 and related proteins
    Patent number: 10093704
    Abstract: The present invention is directed to the cells, compositions and methods for the production of recombinant protein. In particular, the invention is directed to a production process for obtaining high levels of soluble recombinant CRM197 protein from E. coli. Cells preferably contain one or more mutations of disulfide reductase genes, so that disulfide reductase activity is reduced. The invention also relates to purification method for CRM197 as well as characterization of properly folded CRM197 protein.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: October 9, 2018
    Assignee: Fina BioSolutions, LLC
    Inventors: Natalia Oganesyan, Andrew Lees
  • Compositions and methods for brown fat induction and activity using FNDC5
    Patent number: 10093705
    Abstract: The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: October 9, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Pontus Bostrom
  • Dominant positive hnRNP-E1 polypeptide compositions and methods
    Patent number: 10093706
    Abstract: Described herein are compositions relating to engineered hnRNP-E1 variant polypeptides, nucleic acids encoding such polypeptides, engineered hnRNP-E1 compositions, and methods of use thereof. In some embodiments, the engineered hnRNP-E1 polypeptide contains a C293S substitution and retains the ability to bind to a poly(rC)- and poly(U)-rich 5?-UTR element in its cognate mRNA targets in the absence of homocysteine. In some cases, the engineered hnRNP-E1 compositions provided herein are useful to increase the translation of a subset of mRNAs or to treat certain health conditions as described herein.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: October 9, 2018
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Asok C. Antony, Ying-Sheng Tang
  • Antagonists of activin-ActRIIa and uses for increasing red blood cell levels
    Patent number: 10093707
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: October 9, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Interleukin-4 receptor-binding fusion proteins and uses thereof
    Patent number: 10093708
    Abstract: The present invention relates to interleukin-4 receptor binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 receptor binding protein moiety joined to a pro-apoptotic Bcl-2 family member protein moiety.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: October 9, 2018
    Assignee: Medicenna Therapeutics Inc.
    Inventor: Fahar Merchant
  • GM-CSF and IL-4 conjugates, compositions, and methods related thereto
    Patent number: 10093709
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: October 9, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Jiusheng Deng
  • Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia
    Patent number: 10093710
    Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: October 9, 2018
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: George N. Pavlakis, Barbara K. Felber, Antonio Valentin, Cristina Bergamaschi
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 10093711
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: October 9, 2018
    Assignee: Amgen Inc.
    Inventor: Gunasekaran Kannan
  • Immunostimulatory compositions and uses thereof
    Patent number: 10093712
    Abstract: The present invention provides novel immune-stimulatory polypeptides, and methods for their use and identification.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: October 9, 2018
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, Valerie Jacobs, Kenneth Hoober
  • GIP-GLP-1 dual agonist compounds and methods
    Patent number: 10093713
    Abstract: The present invention relates to acylated GIP analogs which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: October 9, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
  • Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof
    Patent number: 10093714
    Abstract: Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: October 9, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Petra Rueger, Tilman Schlothauer, Stefan Seeber
  • Peptides and combination of peptides for use in immunotherapy against various tumors
    Patent number: 10093715
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 9, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Methods for treating cancer
    Patent number: 10093716
    Abstract: The present invention relates to methods and materials for treating an individual with KRAS-mutated cancer or a cancer in which ROCK is inhibited independently of mutated KRAS. The invention is based on the prevention or disruption of the binding of TRAIL-Receptor to its ligand, TRAIL, in vivo, for example by use of an agent that neutralizes TRAIL and/or a the TRAIL-Receptor (such TRAIL-R2) and/or diminishes TRAIL/TRAIL-Receptor activity, thereby reducing cancer cell transformation, migration and metastasis, prolonging survival of patients.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 9, 2018
    Assignee: UCL BUSINESS PLC
    Inventors: Henning Walczak, Silvia Von Karstedt
  • Chimeric antigen receptor containing a toll-like receptor intracellular domain
    Patent number: 10093717
    Abstract: The present invention relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their use in manufacturing drugs for treating tumors. The chimeric antigen receptor of the present invention is characterized by its intracellular domain including at least Toll-like receptor 1 and/or Toll-like receptor 2 intracellular domain(s); compared to the prior art, the chimeric antigen receptors of the present invention has significant advantages in T cell expansion, cytotoxicity, T cell invasion and migration, eliminating immunosuppressive effect of regulatory T cells and promoting the formation of memory T cells, etc.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 9, 2018
    Assignee: SHENZHEN IN VIVO BIOMEDICINE TECHNOLOGY LIMITED COMPANY
    Inventors: Peng Li, Yunxin Lai, Simiao Lin, Yao Yao
  • T1R taste receptors and genes encoding same
    Patent number: 10093718
    Abstract: Methods are provided for identifying human and non-human primate cells which respond to sweet tastants. These methods screen for human or non-human primate cells which express a polypeptide which binds to or responds to sweet tastants. These cells may be used in binding and functional assays to screen for compounds which modulate sweet taste.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: October 9, 2018
    Assignee: Senomyx, Inc.
    Inventors: Jon Elliot Adler, Sergey Zozulya, Xiaodong Li, Shawn O'Connell, Lena Luukkonen
  • Methods for producing stabilized human IgG2 and IgG3 antibodies
    Patent number: 10093719
    Abstract: It is intended to provide highly stable variants of human antibody IgG2 and IgG3 subclasses. The present invention provides an IgG heavy chain comprising the constant region of a human IgG2 heavy chain having at least a substitution of Y for F at the 300th position, L for V at the 309th position, or A for T at the 339th position designated by the EU index of Kabat et al. and an IgG heavy chain comprising the constant region of a human IgG3 heavy chain having at least a substitution of K for N at the 392nd position or V for M at the 397th position designated by the EU index of Kabat et al. The present invention also provides monoclonal antibodies comprising these heavy chains.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: October 9, 2018
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Nobuaki Takahashi, Hideaki Yoshida
  • Broadly neutralizing antibody and uses thereof
    Patent number: 10093720
    Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: October 9, 2018
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITY
    Inventors: Dennis R. Burton, Marit J. van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok
  • Nucleotide sequences, vectors and host cells
    Patent number: 10093722
    Abstract: The present invention relates to fusion proteins comprising fragments from toxin A and/or toxin B of Clostridium difficile, wherein the polypeptide elicits antibodies that neutralize toxin A or toxin B or both.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: October 9, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Cindy Castado
  • Anti-tenascin C antibodies and uses thereof
    Patent number: 10093723
    Abstract: There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 9, 2018
    Assignee: Nascient Limited
    Inventors: Kim Suzanne Midwood, Philip Antony Bland-Ward, Nigel Burns, Patrick John Hextall, Susan Rebecca Aungier
  • Methods of treating a complement associated eye condition by administering complement factor Bb antibodies
    Patent number: 10093724
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 9, 2018
    Assignee: Allergan, Inc.
    Inventors: Yanbin Liang, Chen Li, Iris Lee, Victor M. Guzman
  • Anti-NGF antibodies and their use
    Patent number: 10093725
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 9, 2018
    Assignee: ZOETIS BELGIUM S.A.
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Protein sustained-release injectable formulation
    Patent number: 10093726
    Abstract: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: October 9, 2018
    Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
    Inventors: Lutz Asmus, Michael Möller, Robert Gurny, John P. A. Grimshaw